|
|
| Parise,E.; Cheinquer,H.; Crespo,D.; Meirelles,A.; Martinelli,A.; Sette,H.; Gallizi,J.; Silva,R.; Lacet,C.; Correa,E.; Cotrim,H.; Fonseca,J.; Paraná,R.; Spinelli,V.; Amorim,W.; Tatsch,F.; Pessoa,M.. |
| Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous nonresponder US patients. We evaluated the effectiveness of peginterferon alfa-2a (40KD) plus ribavirin in Brazilian patients who were relapsers or nonresponders to previous interferon-based therapy. One-hundred-thirty-four patients with biopsy-proven chronic hepatitis C, HCV RNA positive, elevated ALT and who were either relapsers (n=37) or nonresponders (n=97) to at least 24 weeks of conventional interferon/ribavirin therapy were retreated with peginterferon alfa-2a (40KD) 180mg/qw and ribavirin 800mg bid for 48 weeks. Efficacy was assessed... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Peginterferon alfa; Ribavirin; Hepatitis C; Safety; Efficacy. |
| Ano: 2006 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000100003 |
| |
